Francesco Ronchetti

Francesco Ronchetti

Auto-generated profile, based on publicly available information

Francesco Ronchetti

Sapienza Università di Roma, Rome, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
KFKrisstopher Richard Flores
Krisstopher Richard Flores
FVFausta Viccaro
Fausta Viccaro
MAMauro Aquilini
Mauro Aquilini
FRFrancesco Ronchetti
Francesco Ronchetti
Stefania ScarpinoStefania Scarpino
Stefania Scarpino
Alberto RicciAlberto Ricci
Alberto Ricci
Background: OSAS is characterized by a chronic intermittent hypoxia (CIH) and sleep fragmentation. PSG is the gold standard for diagnosis. New biomarkers have been proposed. BDNF is a key mediator of cognitive functions. Changes of BDNF serum levels follow CIH. OSAS patients have mucosal upper airways inflammation. BDNF has been identified in various chronic inflammatory airways diseases. Objectives: BDNF serum levels and mucosal expression in severe OSAS patients compared to controls. Relationship of serum BDNF with neurocognitive function. Changes in serum BDNF after CPAP. Methods: Serum BDNF, upper airways mucosal biopsy and Montreal Cognitive Assestment (MoCA) are performed in 12 naïve severe OSAS patients and in 8 controls. In OSAS patients serum BDNF and MoCA were reassessed after 45 days of CPAP treatment. Results: BDNF in OSAS was significantly higher than controls (p=0.01) and showed a positive correlation with ODI (p=0.01, r=0.6). Serum BDNF had a decreasing trend after CPAP treatment. Before the treatment, MoCA scores were lower in OSAS than controls and are positively correlated with serum BDNF levels (p=0.02, r=0.57). MoCA is normalized by CPAP therapy. Immunohistochemistry of mucosal biopsy in OSAS patients showed higher inflammatory infiltrate CD3+ CD79a+ (BDNF positive) than controls. Conclusions: OSAS patients showed higher serum BDNF levels and lower MoCA scores than controls. The positive correlation between BDNF values and MoCA might reveal a peculiar BDNF-mediated neuroprotective mechanism against neuroinflammation induced by hypoxia. OSAS have mucosal upper airway lymphocytic inflammation BDNF positive.

11 April 2019
Verified
Conference Paper
Closed access
KFKrisstopher Richard Flores
Krisstopher Richard Flores
FVFausta Viccaro
Fausta Viccaro
MAMauro Aquilini
Mauro Aquilini
Stefania ScarpinoStefania Scarpino
Stefania Scarpino
FRFrancesco Ronchetti
Francesco Ronchetti
Alberto RicciAlberto Ricci
Alberto Ricci
Background: OSAS is characterized by a chronic intermittent hypoxia (CIH) and sleep fragmentation. Polysonnography is the standard diagnostic test. New biomarkers have been proposed. The BDNF is a key mediator of neuronal and synaptic plasticity in cognitive functions. Experimental studies demonstrate changes of serum levels of BDNF following CIH Objectives: To determine serum level of BDNF in patients with severe OSAS compared with a control group and its relationship to neurocognitive function. Changes in BDNF serum levels in OSAS patients after CPAP treatment. Methods: Serum BDNF and the Montreal Cognitive Assestment (MoCA) are evaluated in 12 patients with newly diagnosed severe OSAS and in 8 healthy patients (control group). In OSAS patients serum BDNF and MoCA were reassessed after 45 days of CPAP treatment. Results: BDNF in OSAS patients was significantly higher compared to control group (p=0.01) and showed a positive correlation with ODI (p=0.01, r=0.6). Serum BDNF had a decreasing trend after CPAP treatment. Before the treatment, MoCA scores were lower in OSAS patients than controls and are positively correlated with serum BDNF levels (p=0.02, r=0.57). MoCA is normalized by CPAP therapy Conclusions: OSAS patients showed higher serum BDNF levels and lower MoCA scores compared to controls. The positive correlation between BDNF values and MoCA might reveal a peculiar BDNF-mediated neuroprotective mechanism against neuroinflammation induced by hypoxia.